drugset
drugset / Trial / NCT04508894

Ketamine Versus Dexmedetomidine in Supraclavicular Brachial Plexus Block

NCT04508894 ↗

Completed 75 enrolled Minia University
RandomizedParallel-groupDouble-blindTreatment

Summary

Intervention model description: The patients were randomly classified into three groups using computer-generated table numbers each contain (25) patients. Ketamine group (group K): 20 ml 0.5%bupivacaine and 20 ml 0.9% normal saline plus 1 mg\\kg ketamine, Dexmedetomidine group (group D): 20 ml 0.5% bupivacaine and 20 ml 0.9% normal saline plus 1µg\\kg dexmedetomidine Control group (group C): 20 ml 0.5%bupivacaine and 20 ml 0.9% normal saline. Masking: double-blind (participant and investigator) Masking Description: The investigator's study is a prospective, randomized, double-blind

Timeline

Start
2019-04-21
Primary completion
2020-12-28
Completion
2020-12-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexmedetomidine Other / unclassified 1 ug/kg Other
Comparator Ketamine Small molecule 1 mg/kg Other
Comparator Bupivacaine Other / unclassified 20 ml Other
Comparator Diclofenac Other / unclassified 75 mg Intramuscular
Comparator Supraclavicular Brachial Plexus Block with Dexmedetomidine Unknown 20 ml Other
Comparator Supraclavicular Brachial Plexus Block with Ketamine Unknown 20 ml Other

Indications

No indication recorded.